TRACON Pharmaceuticals Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Charles Theuer
Chief executive officer
US$1.1m
Total compensation
CEO salary percentage | 58.6% |
CEO tenure | 18yrs |
CEO ownership | 0.8% |
Management average tenure | 4.2yrs |
Board average tenure | 9.5yrs |
Recent management updates
Recent updates
Tracon Pharmaceuticals announces $35M non-dilutive debt facility
Sep 06Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma
Aug 29Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M
Aug 10TRACON Pharmaceuticals announces $5M registered direct offering
Dec 29TRACON Pharma launches $8.8M direct offering
Dec 22Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study
Dec 10Tracon Pharma files China application for envafolimab in solid tumors
Nov 16CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | US$2m |
Dec 31 2023 | US$1m | US$632k | -US$4m |
Sep 30 2023 | n/a | n/a | -US$11m |
Jun 30 2023 | n/a | n/a | -US$28m |
Mar 31 2023 | n/a | n/a | -US$28m |
Dec 31 2022 | US$1m | US$608k | -US$29m |
Sep 30 2022 | n/a | n/a | -US$30m |
Jun 30 2022 | n/a | n/a | -US$30m |
Mar 31 2022 | n/a | n/a | -US$33m |
Dec 31 2021 | US$2m | US$585k | -US$29m |
Sep 30 2021 | n/a | n/a | -US$25m |
Jun 30 2021 | n/a | n/a | -US$22m |
Mar 31 2021 | n/a | n/a | -US$18m |
Dec 31 2020 | US$1m | US$568k | -US$17m |
Sep 30 2020 | n/a | n/a | -US$16m |
Jun 30 2020 | n/a | n/a | -US$18m |
Mar 31 2020 | n/a | n/a | -US$19m |
Dec 31 2019 | US$1m | US$553k | -US$23m |
Sep 30 2019 | n/a | n/a | -US$26m |
Jun 30 2019 | n/a | n/a | -US$30m |
Mar 31 2019 | n/a | n/a | -US$34m |
Dec 31 2018 | US$1m | US$542k | -US$35m |
Sep 30 2018 | n/a | n/a | -US$34m |
Jun 30 2018 | n/a | n/a | -US$24m |
Mar 31 2018 | n/a | n/a | -US$20m |
Dec 31 2017 | US$1m | US$532k | -US$19m |
Compensation vs Market: Charles's total compensation ($USD1.08M) is above average for companies of similar size in the US market ($USD683.22K).
Compensation vs Earnings: Charles's compensation has been consistent with company performance over the past year.
CEO
Charles Theuer (60 yo)
18yrs
Tenure
US$1,078,633
Compensation
Dr. Charles P. Theuer, M.D. & Ph D., has been the President and Chief Executive Officer of Tracon Pharmaceuticals, Inc. since July 2006 and has been its Director of Tracon Pharmaceuticals, Inc. since June...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman | 18yrs | US$1.08m | 0.76% $ 32.5k | |
Chief Financial Officer | 5.5yrs | US$590.49k | 0.047% $ 2.0k | |
Chief Medical Officer | 4.2yrs | no data | no data | |
Executive Director of Statistical Programming | 3.1yrs | no data | no data | |
Chief Business Development Officer | less than a year | no data | no data |
4.2yrs
Average Tenure
51.5yo
Average Age
Experienced Management: TCON's management team is considered experienced (4.2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman | 18yrs | US$1.08m | 0.76% $ 32.5k | |
Independent Director | 9.4yrs | US$75.65k | 0.0014% $ 60.9 | |
Independent Director | 10yrs | US$84.40k | 0.014% $ 620.7 | |
Independent Director | 9.6yrs | US$78.15k | 0.0014% $ 60.9 | |
Independent Director | 4.3yrs | US$79.40k | 0.022% $ 963.2 | |
Independent Director | 15.8yrs | US$69.40k | 0.0014% $ 60.9 | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Independent Director | 2.8yrs | US$69.40k | 0% $ 0 | |
Independent Director | 3.3yrs | US$68.15k | 0% $ 0 |
9.5yrs
Average Tenure
65yo
Average Age
Experienced Board: TCON's board of directors are considered experienced (9.5 years average tenure).